News

Combined dermatology-rheumatology clinics improve care, spark new research


 

References

Dr. Ogdie-Beatty’s clinic is participating in a variety of research studies, including an analysis of vascular inflammation in psoriasis patients. The study is examining markers of early joint inflammation among psoriasis patients who don’t have symptoms of joint pain. Another initiative focuses on how to implement psoriasis and PsA disease activity measures into the medical record, Dr. Ogdie-Beatty said.

At a combined dermatology-rheumatology clinic within the University Health Network, Toronto, doctors are studying the incidence of arthritis and comorbidities in patients with psoriasis, said Dr. Vinod Chandran, a rheumatologist at the University of Toronto. Another ongoing study focuses on identifying risk factors for PsA in patients with psoriasis. The Toronto clinic is participating in the studies as part of the International Psoriasis and Arthritis Research Team.

Dr. Vinod Chandran

Dr. Vinod Chandran

“There are a number of research opportunities in the combined clinic since a detailed clinical evaluation is extremely important in biomarker and translational studies,” said Dr. Chandran, who codirects the psoriatic arthritis program at the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto. “The clinic also provides an opportunity to participate in phase II and III clinical trials.”

Managing the combined derm-rheum clinics does come with challenges, doctors said. The obstacles are primarily logistical, and include identifying the space, time, and scheduling for the clinic, Dr. Garg said. Other challenges revolve around reimbursement, such as figuring out the best payment structure and ensuring that insurers will cover the simultaneous care, Dr. Merola said. Generally, it also takes longer to see the patient, and physicians may not be able to see as many patients together per day as they could alone, he added. However, physicians stress that the benefits of the combined clinics far outweigh the negatives.

“We’ve always felt the value has been there because we feel the patients really appreciate the service,” he said. “And we think the quality of care around what we do is better.”

agallegos@frontlinemedcom.com

On Twitter@legal_med

Pages

Recommended Reading

WCD: Look for TNF inhibitor–induced psoriasis in kids
MDedge Dermatology
Methotrexate ups risk of liver abnormalities, but not serious hepatic events
MDedge Dermatology
Tissue-based treatment could improve psoriatic arthritis outcomes
MDedge Dermatology
PsA, PsC do not affect total hip replacement outcomes
MDedge Dermatology
FUTURE 1 trial results fortify evidence base for secukinumab’s efficacy in psoriatic arthritis
MDedge Dermatology
Large study identifies psoriasis as an independent risk factor for major depression
MDedge Dermatology
Improvements seen in adolescent psoriasis with ustekinumab
MDedge Dermatology
Brodalumab psoriasis results published, development plans continue
MDedge Dermatology
PsA confers higher risk of cardiovascular disease, events
MDedge Dermatology
Psoriasis severity correlates with aortic vascular inflammation
MDedge Dermatology